EU/US MRA (mutual recognition agreement) delay may not last two years, say regulators
This article was originally published in Clinica
A full two-year delay to the Mutual Recognition Agreement (MRA) between the EU and the US may not be necessary, industry heard from regulators on the second day of the US/EU MRA meeting on December 5 in Brussels last week. If both parties are able to find solutions to the problem issues and to complete the appointment of two conformity assessment bodies (CABs) on each side, then the MRA could come into force earlier.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.